CN108239185A - A kind of inclusion compound of quinindium and amine cyclodextrin - Google Patents

A kind of inclusion compound of quinindium and amine cyclodextrin Download PDF

Info

Publication number
CN108239185A
CN108239185A CN201810000390.0A CN201810000390A CN108239185A CN 108239185 A CN108239185 A CN 108239185A CN 201810000390 A CN201810000390 A CN 201810000390A CN 108239185 A CN108239185 A CN 108239185A
Authority
CN
China
Prior art keywords
cyclodextrin
quinindium
inclusion compound
amine
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810000390.0A
Other languages
Chinese (zh)
Inventor
廖霞俐
周诚
宋爽
杨波
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kunming University of Science and Technology
Original Assignee
Kunming University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kunming University of Science and Technology filed Critical Kunming University of Science and Technology
Priority to CN201810000390.0A priority Critical patent/CN108239185A/en
Publication of CN108239185A publication Critical patent/CN108239185A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/49Cinchonan derivatives, e.g. quinine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention discloses the inclusion compound of a kind of quinindium and amine cyclodextrin, belongs to pharmaceutical technology field.Amine cyclodextrin is the beta cyclodextrin of amino substitution in the present invention, its inclusion compound with quinindium is prepared using solvent method or ultrasonic method, inclusion compound is formed using amine cyclodextrin and quinindium, other than the clathration of cyclodextrin cavity and quinindium, alkaline environment can be formed in aqueous solution, and ionic interaction is formed with the hydroxyl of quinindium;Amino can form cation in water simultaneously, hydrogen bond action occur with the nitrogen-atoms on quinindium molecule, therefore be more advantageous to the water solubility and stability of enhancing inclusion compound.Inclusion compound stability provided by the present invention is high, good water solubility, is expected to improve the bioavilability of quinindium.Preparation method simplicity, mild condition, easy to operate, suitable commercial Application simultaneously.

Description

A kind of inclusion compound of quinindium and amine cyclodextrin
Technical field
The present invention relates to a kind of quinindiums and the inclusion compound of amine cyclodextrin, belong to pharmaceutical technology field.
Background technology
Malaria is that most one of disease of infectiousness and life-threatening, the whole world have more than 300,000,000 people and is infected, wherein flat There is more than 100 ten thousand people death every year.Although malaria is in the world, numerously area has been eliminated extensively, and malaria infection case sum is still Rising year by year.Cinchona alkaloid quinindium(English name Quinidine, structure is as shown in Formula II)It is that the first kind is applied to malaria One of drug of disease people, this drug are found almost without side effect.Meanwhile quinindium is also with some other important Bioactivity, such as heat resistanceheat resistant, anti-arrhythmia.However, due to the poorly water-soluble of quinindium, body is caused to absorb oral medication It is bad and irregular, significantly limit its application;Therefore, there is an urgent need to a kind of efficient, nontoxic carrier, to increase its clinic The oral administration biaavailability of application.
Cyclodextrin(Cyclodextrin, abbreviation CD)It is one that amylose generates under cyclodextrin glycosyltransferase effect The general name of series of annular oligosaccharides, wherein using it is more be the molecule containing 6,7 or 8 glucose sugar units, respectively α-, β-and Gamma-cyclodextrin;Form cyclodextrin molecular each D- glucopyranoses be chair conformation, each glucose unit with α-Isosorbide-5-Nitrae- Glucosides key connection cyclization;Since the glycosidic bond of connection glucose unit cannot rotate freely, cyclodextrin forms both ends open, one end The small and hollow truncated cone shape stereochemical structure in big one end;In its cavity structure, intracavitary portion is due to the shielding action by C-H keys Foring hydrophobic region, and all hydroxyls are then outside cavity, wherein C-2 and C-3 secondary hydroxyls are distributed in big opening end, and C-6 Primary hydroxyl is distributed in osculum end;Such stereochemical structure causes cyclodextrin to have outer hydrophilic, interior hydrophobic peculiar property;It is three-dimensional Structure is as follows:
Wherein, n=1,2 or 3, correspond to respectively α-, β-and gamma-cyclodextrin.
After drug molecule forms inclusion compound with cyclodextrin and its derivative, drug water solubility can be enhanced, improve its stability, Its bad smell can be also covered, reduces its irritation in gastrointestinal tract with adverse reaction and extends release time and the raising of drug The bioavilability of drug, and with Colon and rectum targeting.Meanwhile it can effectively avoid or reduce using cyclodextrin inclusion technique The use of solvent, surfactant and lipid.Cyclodextrin inclusion compound biggest advantage is that it can change medicine from molecular level The property of object and to the pharmacokinetics process of drug almost without interference.There are about 30 kinds of drugs containing cyclodextrin in the world at present Preparation lists, and the effect of cyclodextrin in these formulations is mainly:It is organic in replacement injection or topical application preparation prescription Solvent;Improve the oral administration biaavailability of the IIth class and some the IVth class drugs;It reduces GI irritation and increases the saturating of drug Skin diffusivity etc..By animal and human experimentation, research shows that, cyclodextrin can improve the cross-film of nearly all types of drug Transhipment.
In three kinds of common cyclodextrin described above, beta-cyclodextrin due to it is cheap and easy to get, be of moderate size and nontoxic etc. excellent Benign matter and most widely applied, but the water solubility and Binding ability of beta-cyclodextrin are limited, as inclusion main body point Son is often difficult to the requirement for meeting medicinal application;Therefore, how to carry out appropriate structural modification to beta-cyclodextrin is this field skill The emphasis of art personnel research and development.
Invention content
The purpose of the present invention is to provide a kind of quinindiums and amine with higher stability, water solubility and bioavilability The inclusion compound of class cyclodextrin, the inclusion compound contain quinindium and amine cyclodextrin, and the amine cyclodextrin is mono-substituted for 6- Beta-cyclodextrin, shown in structural formula as I:
Formulas I
Wherein, the arbitrary value in n 0,1,2 and 3, corresponding amine cyclodextrin are followed successively by:Single-(6- amino -6- deoxidations)-β- Cyclodextrin, list-(6- ethylenediamine -6- deoxidations)Beta-cyclodextrin, list-(6- diethylenetriamine -6- deoxidations)Beta-cyclodextrin and single- (6- triethylene tetramine -6- deoxidations)Beta-cyclodextrin.
The inclusion compound of quinindium of the present invention and amine cyclodextrin is prepared using solvent inclusion method or ultrasonic method, The molar ratio of middle quinindium and amine cyclodextrin is 1:2~1:10.
Preparation process using solvent inclusion method is as follows:While stirring to the water dissolved with amine cyclodextrin at 25 ~ 50 DEG C Quinindium is added in solution, is continued after being protected from light 36 ~ 72 h of stirring, filters off insoluble matter, evaporated under reduced pressure solvent is up to quinindium and amine The inclusion compound of class cyclodextrin.
It is as follows using the preparation process of ultrasonic method:Amine cyclodextrin at 25 ~ 50 DEG C into sonic oscillation is water-soluble Quinindium is added in liquid, is then proceeded to after being protected from light 1 ~ 10 h of ultrasound, filters off insoluble matter, evaporated under reduced pressure solvent is up to quinindium and amine The inclusion compound of class cyclodextrin.
The present invention uses amido modified beta-cyclodextrin, amine cyclodextrin is formed, in addition to cyclodextrin cavity and the packet of quinindium Outside cooperation, alkaline environment can be formed in aqueous solution, and ionic interaction is formed with the hydroxyl of quinindium;Amino is in water simultaneously In can form cation, on quinindium molecule nitrogen-atoms occur hydrogen bond action, therefore be more advantageous to enhancing inclusion compound water Dissolubility and stability.
Amine cyclodextrin of the present invention is C-6 hydroxyls of D- glucopyranoses of beta-cyclodextrin molecule by different ammonia The derivative of base substitution generation.
The synthetic method of amine cyclodextrin is as follows:First, C-6 hydroxyls of beta-cyclodextrin are carried out with paratoluensulfonyl chloride single Sulfonylation obtains single 6-OTs- β-CD.Synthesis it is single-(6- amino -6- deoxidations)During beta-cyclodextrin, first by single 6-OTs- β-CD Tolysulfonyl oxygen groups(-OTs)Use azido group(-N3)Substitution;Azido group is finally reduced to ammonia with triphenylphosphine Base i.e. obtain target compound list-(6- amino -6- deoxidations)Beta-cyclodextrin;Its synthetic reaction formula is as shown in formula III:
Formula III
And synthesis it is single-(6- ethylenediamine -6- deoxidations)Beta-cyclodextrin, list-(6- diethylenetriamine -6- deoxidations)Beta-cyclodextrin and Single-(6- triethylene tetramine -6- deoxidations)During beta-cyclodextrin, single 6-OTs- β-CD with aminated compounds are reacted and generate these three Amine cyclodextrin.Wherein, the aminated compounds is respectively ethylenediamine, diethylenetriamine and triethylene tetramine.Its synthetic reaction Formula is as shown in formula IV:
Formula III
Wherein, n=0,1 or 2, corresponding aminated compounds are ethylenediamine, diethylenetriamine and triethylene tetramine.
Beneficial effects of the present invention:
(1)The inclusion compound of the amine cyclodextrin of quinindium provided by the present invention, quinindium respectively with it is single-(6- amino -6- takes off Oxygen)-beta-cyclodextrin, list-(6- ethylenediamine -6- deoxidations)-beta-cyclodextrin, list-(6- diethylenetriamine -6- deoxidations)-beta-cyclodextrin Or solubility difference of the inclusion compound that is formed of list-(6- triethylene tetramine -6- deoxidations)-beta-cyclodextrin in the water of pH=7.5 Improve 8.3,6.5,7.5 and 10.0 times;Wherein with list-(6- triethylene tetramine -6- deoxidations) increasing of-beta-cyclodextrin to quinindium Molten effect is best.
(2)The preparation method of inclusion compound of the present invention is easy, easy to operate, mild condition, is suitble to industrialized production.
Description of the drawings
Fig. 1 is list-(6- amino -6- deoxidations)-beta-cyclodextrin and quinindium and its solid clathrates1H-NMR compares figure;
Fig. 2 is list-(6- ethylenediamine -6- deoxidations)-beta-cyclodextrin and quinindium and its solid clathrates1H-NMR compares figure;
Fig. 3 is list-(6- diethylenetriamine -6- deoxidations)-beta-cyclodextrin and quinindium and its solid clathrates1H-NMR compares Figure;
Fig. 4 is list-(6- triethylene tetramine -6- deoxidations)-beta-cyclodextrin and quinindium and its solid clathrates1H-NMR compares Figure.
Fig. 5 is the uv absorption spectra of quinindium(The nm of pH=7.5, λ=330);
Fig. 6 is concentration-absorbance standard curve figure of quinindium.
Specific embodiment
Further heretofore described method is described below by embodiment, but the scope of the present invention is not by reality Example limitation is applied, the reagent used in the present embodiment is conventional commercial reagent or the examination prepared according to a conventional method unless otherwise specified Agent, the method used are conventional method unless otherwise specified.
Embodiment 1
The preparation of quinindium and list-(6- amino -6- deoxidations)-Benexate Hydrochloride
(1)The preparation of single -6-OTs- β-CD
210 g of beta-cyclodextrin that water recrystallized is taken, the three-necked bottle for filling 1300 mL water is added portionwise(3 L)In, room temperature is stirred It mixes;It weighs 17.2 g sodium hydroxides to be dissolved in 50 mL water, then slowly be added dropwise in the suspension of beta-cyclodextrin It is gradually clarified to reaction solution, continues to stir 1.5 h;After reaction solution cyclodextrin is completely dissolved change clarification, 26.0 will be contained G paratoluensulfonyl chlorides are dissolved in 80 mL acetonitriles ultrasounds to clarifying, and solution is slowly added dropwise into reaction solution(It drips off within about 30 minutes), after After 2 h of continuous stirring, insoluble matter is filtered off, filtrate is adjusted with the hydrochloric acid of 2 mol/L to pH=7.5, there are a large amount of white precipitates to analyse at this time Go out.Collected by suction precipitates, and is dissolved in sediment in the distilled water of 450 mL under heating condition, filters insoluble matter, filtrate chamber while hot Temperature stands 12 h, collects sediment, and heating cools down recrystallization for several times, until thin-layer chromatography shows products pure.
Obtain 17.5 g of final product, yield 8.2%;It is measured by NMR spectrum method, product structure characterizes such as Under:1H-NMR (500 MHz, DMSO-d 6, ppm):δ 2.44(s,3H, -CH3), 3.20-3.71 (m, 42H, H-2, -3, - 4, -5, -6 of β-CD), 4.30-4.45 (m, 6H, 6-OH of β-CD), 4.86 (s, 7H, H-1 of β-CD), 5.66-5.90 (m, 14H, 2-, 3- OH of β-CD), 7.43-7.40 (d, 2H, Ar-H), 7.74-7.77 (d, 2H, Ar-H)。
(2)Single -6-N3The preparation of-β-CD
By 6.5 g(5.0 mmol)Single 6-OTs- β-CD are dissolved in the DMF of 15 mL dryings, are stirred at room temperature to being completely dissolved, then Add in Sodium azide(0.4 g, 6.15 mmol), under nitrogen protections, 10 h are reacted at 75 DEG C, treat to be cooled to room after reaction Reaction solution is slowly dropped into 300 mL acetone by temperature, and after stirring 30 min, suction filtration takes filter cake, and vacuum drying obtains white powder 5.0 g, yield 85.1%.
(3)The preparation of list-(6- amino -6- deoxidations)-beta-cyclodextrin
It will single -6- N3-β-CD(1.5 g, 1.32 mmol)It is dissolved in 20 mL dryings DMF, adds in triphenylphosphine(1.7g 6.49 mmol), 2 h are stirred at 25 DEG C;7 mL ammonium hydroxide are slowly added to, the reaction was continued 18 h are filtered to remove insoluble matter, will clarify Liquid is slowly dropped into 300 mL acetone, and filter cake is filtered to take after stirring 30 min, is dried in vacuo, is obtained 0.95 g of white powder, yield 62.3%。
(4)The preparation of quinindium and list-(6- amino -6- deoxidations)-Benexate Hydrochloride
List-(6- amino -6- deoxidations)-beta-cyclodextrin is added in the reaction bulb of 25 mL(7.9g, 7 mmol)Add in 20 mL's Distilled water is stirred to dissolving, then adds in quinindium(0.45g, 1 mmol)Ethanol solution, 5 h of ultrasound are protected from light at 25 DEG C, Be filtered to remove undissolved solid drugs, then with 0.45 μm of filtering with microporous membrane, then filtrate decompression is evaporated can obtain it is white Color powder, dry 24 h are to get the powdered of quinindium and list-(6- amino -6- deoxidations)-beta-cyclodextrin in vacuum drying chamber Solid clathrates, inclusion compound1H-NMR is shown in Fig. 1, and A is quinindium in figure(DMSO-d 6), B be inclusion compound(D2O), C be list-(6- ammonia Base -6- deoxidations)-beta-cyclodextrin(D2O).Since quinindium is not soluble in water, therefore it can not D2O detects NMR signal;And scheme clear in B The clear related proton signal for showing quinindium illustrates that it forms inclusion compound with list-(6- amino -6- deoxidations)-beta-cyclodextrin.
Embodiment 2
The preparation of quinindium and list-(6- ethylenediamine -6- deoxidations)-Benexate Hydrochloride
(1)Steps of single -6-OTs- β-CD during the preparation method is the same as that of Example 1(1).
(2)The preparation of list-(6- ethylenediamine -6- deoxidations)-beta-cyclodextrin
By 3.0 g(2.3 mmol)6-OTs- β CD are dissolved in the ethylenediamine that 20 mL molecular sieves have been dried, and are stirred at room temperature to complete It dissolves, reacts 10 h under 80 DEG C of nitrogen protective conditions, after complete reaction, decompression boils off solvent, and a small amount of water is added into reaction bulb Dissolved solid continues that solvent is evaporated off, and then adds in 2 mL water dissolution products, and be slowly dropped into 400 mL acetone, room Temperature 30 min of stirring, collected by suction white precipitate, and obtained solid crude product is dried into 24 h in vacuum drying chamber.It will dry Solid powder be again dissolved in 2 mL distilled water, be filtered to remove a small amount of insoluble matter, filtrate is instilled in 300 mL acetone, is collected white Color precipitates.Aforesaid operations are repeated to thin-layer chromatography detection free from admixture point to get to pure list-(6- ethylenediamine -6- deoxidations)-β-ring Dextrin(2.4 g), yield 87.6%.
(3)The preparation of quinindium and list-(6- ethylenediamine -6- deoxidations)-Benexate Hydrochloride
List-(6- ethylenediamine -6- deoxidations)-beta-cyclodextrin is added in 25 mL reaction bulbs(3528 mg, 3 mmol)And add in 20 ML distilled water is stirred to dissolving, then adds in quinindium(456 mg, 1 mmol)Methanol solution, stirring 72 is protected from light at 25 DEG C H, is filtered to remove undissolved solid, then with 0.45 μm of filtering with microporous membrane, and filtrate is evaporated to obtain white powder, then in vacuum Pulverulent solids inclusion compounds of 24 h to get quinindium and list-(6- ethylenediamine -6- deoxidations)-beta-cyclodextrin is dried in drying box, Its1H-NMR is shown in Fig. 2, and A is quinindium in figure(DMSO-d 6), B be inclusion compound(D2O), C for list-(6- ethylenediamine -6- deoxidations)-β - Cyclodextrin(D2O).Since quinindium is not soluble in water, therefore it can not D2O detects NMR signal;And scheme clearly to show Kui Ni in B The related proton signal of fourth illustrates that it forms inclusion compound with list-(6- ethylenediamine -6- deoxidations)-beta-cyclodextrin.
Embodiment 3
The preparation of quinindium and list-(6- diethylenetriamine -6- deoxidations)-Benexate Hydrochloride
(1)Single -6-OTs- β-CD steps that the preparation method is the same as that of Example 1(1).
(2)The preparation of list-(6- diethylenetriamine -6- deoxidations)-beta-cyclodextrin
By 3.0 g(2.3 mmol)Single 6-OTs- β-CD are dissolved in the diethylenetriamine of 20 mL dryings, are stirred at room temperature to completely molten Solution under nitrogen protection, 10 h is reacted at 80 DEG C, treat after reaction, reaction solution to be slowly dropped into 400 mL acetone, room temperature It after stirring 30 min, filters and removes filtrate, collect white precipitate, precipitation is dissolved in a small amount of water, and be further dropped into 300 mL In acetone, collected by suction white precipitate after 0.5 h is stirred, drying in vacuum drying chamber, obtained solid powder is ground by it After add in 200 mL ethyl alcohol, 20 min of ultrasound, collect white precipitate.It repeats aforesaid operations to thin-layer chromatography and detects free from admixture Point is to get pure list-(6- diethylenetriamine -6- deoxidations)-beta-cyclodextrin(2.1 g), yield 74.4%.
(3)The preparation of quinindium and list-(6- diethylenetriamine -6- deoxidations)-Benexate Hydrochloride
List-(6- diethylenetriamine -6- deoxidations)-beta-cyclodextrin is added in the reaction bulb of 25 mL(6095 mg, 5 mmol)And It adds in 20 mL distilled water to stir to dissolving, then adds in quinindium(456 mg, 1 mmol)Ethanol solution, kept away at 25 DEG C Light 10 h of ultrasound, are filtered to remove undissolved solid, then with 0.45 μm of filtering with microporous membrane, are then evaporated filtrate decompression White powder can be obtained, in vacuum drying chamber dry 24 h to get quinindium and list-(6- diethylenetriamine -6- deoxidations)-β - The pulverulent solids inclusion compound of cyclodextrin, inclusion compound1H-NMR is shown in Fig. 3, and A is quinindium in figure(DMSO-d 6), B be inclusion compound (D2O), C be list-(6- diethylenetriamine -6- deoxidations)-beta-cyclodextrin(D2O).Since quinindium is not soluble in water, therefore it can not D2O Detect NMR signal;And scheme clearly to show the related proton signal of quinindium in B, illustrate its with list-(6- divinyls three Amine -6- deoxidations)-beta-cyclodextrin formation inclusion compound.
Embodiment 4
The preparation of quinindium and list-(6- triethylene tetramine -6- deoxidations)-Benexate Hydrochloride
(1)Single 6-OTs- β-CD the step of the preparation method is the same as that of Example 1(1).(2)Single-(6- triethylene tetramine -6- deoxidations) - The preparation of beta-cyclodextrin
By 3.0 g(2.3 mmol)Single 6-OTs- β-CD are dissolved in the triethylene tetramine of 20 mL dryings, are stirred at room temperature to completely molten Solution under nitrogen protection, reacts 12 h in 85 DEG C, treats after reaction, reaction solution to be slowly dropped into 400 mL acetone, room temperature is stirred It after mixing 30 min, filters and removes filtrate, collect white precipitate, precipitation is dissolved in a small amount of water, and be further dropped into 300 mL third In ketone, collected by suction white precipitate after 0.5 h is stirred, drying in vacuum drying chamber by it, after obtained solid powder is ground It adds in 200 mL ethyl alcohol, 20 min of ultrasound, collects white precipitate.It repeats aforesaid operations to thin-layer chromatography and detects free from admixture point, Up to pure list-(6- triethylene tetramine -6- deoxidations)-beta-cyclodextrin(1.59 g), yield 54%.
(3)The preparation of quinindium and list-(6- triethylene tetramine -6- deoxidations)-Benexate Hydrochloride
List-(6- triethylene tetramine -6- deoxidations)-beta-cyclodextrin is added in 25 mL reaction bulbs(6876 mg, 4 mmol)It adds in 20 mL distilled water are stirred to dissolving, then add in quinindium(456 mg, 1 mmol), 7 h of ultrasound are protected from light at 25 DEG C, are filtered It removes undissolved solid, then with 0.45 μm of filtering with microporous membrane, filtrate decompression is then evaporated to obtain white powder, then Dry 24 h are to get the powdered solid of quinindium and list-(6- triethylene tetramine -6- deoxidations)-beta-cyclodextrin in vacuum drying chamber Body inclusion compound, inclusion compound1H-NMR is shown in Fig. 4 figures that A is quinindium(DMSO-d 6), B be inclusion compound(D2O), C be list-(tri- second of 6- Alkene tetramine -6- deoxidations)-beta-cyclodextrin(D2O).Since quinindium is not soluble in water, therefore it can not D2O detects NMR signal;And scheme B In clearly show the related proton signal of quinindium, illustrate its with list-(6- triethylene tetramine -6- deoxidations)-beta-cyclodextrin Form inclusion compound.
The quinindium that embodiment 1 ~ 4 is prepared is measured with the water-soluble of the inclusion compound of amine cyclodextrin
(1)The measure of quinindium solubility criteria curve
A series of concentration ranges of accurate formulation are 8.5 ~ 13.9 × 10-5 The quinindium aqueous solution of mol/L, uses uv-spectrophotometric Meter measures the ultraviolet absorption value A at 330 nm of wavelength at its 25 DEG C, then with concentration C(mol/L)For abscissa, with absorbance A For ordinate fit standard curve A=5157C-0.02712;R2 = 0.996(Quinindium is in the buffer solution of pH=7.5 UV absorption intensity is with concentration at 330 nm(0.085~0.139 mM)Change curve is shown in Fig. 5;Standard curve is shown in Fig. 6).
(2)The measure of inclusion compound solubility in water
Be separately added into the reaction bulb of 10 mL 0.1 mmol it is mono--(6- amino -6- deoxidations)-beta-cyclodextrin, list-(6- second two Amine -6- deoxidations)-beta-cyclodextrin, list-(6- diethylenetriamine -6- deoxidations)-beta-cyclodextrin or list-(6- triethylene tetramines -6- takes off Oxygen)-beta-cyclodextrin.Then 2 mL distilled water are added in stir to dissolving, 0.3 mmol quinindiums is added, is protected from light stirs at room temperature It mixes 3 days;It is finally the saturated solution for the amine cyclodextrin for obtaining quinindium with 0.45 μm of filtering with microporous membrane.It is surveyed after dilution Its UV absorption intensity(A values is made to fall 0.3 ~ 0.8).
List-(6- amino -6- deoxidations)-beta-cyclodextrin, the list-(6- second two of quinindium are measured by ultraviolet specrophotometer Amine -6- deoxidations)-beta-cyclodextrin, list-(6- diethylenetriamine -6- deoxidations)-beta-cyclodextrin, list-(6- triethylene tetramines -6- takes off Oxygen)-beta-cyclodextrin and quinindium saturated aqueous solution absorption value A;The extension rate of saturated aqueous solution and corresponding ultraviolet suction Receipts value is:51/0.359、31/0.472、28/0.612、61/0.360、5/0.446;Quinindium is calculated by standard curve List-(6- amino -6- deoxidations)-beta-cyclodextrin, list-(6- ethylenediamine -6- deoxidations)-beta-cyclodextrin, list-(6- diethylenetriamines - 6- deoxidations)-beta-cyclodextrin, list-(6- triethylene tetramine -6- deoxidations)-beta-cyclodextrin and quinindium pH=7.5 under 20 oC Solubility is respectively in water:3.81×10-3mol/L、3.01×10-3 mol/L、3.47×10-3 mol/L、4.58×10- 3Mol/L and 4.59 × 10-4Mol/L is respectively increased:8.3rd, 6.5,7.5 and 10.0 times.
After being included with amine cyclodextrin, the solubility of quinindium in water is improved, and its solubilising is made With most strong for list-(6- triethylene tetramine -6- deoxidations)-beta-cyclodextrin.

Claims (4)

1. a kind of inclusion compound of quinindium and amine cyclodextrin, it is characterised in that:The amine cyclodextrin is mono-substituted for 6- Beta-cyclodextrin, shown in structural formula as I:
Formulas I
Wherein, the arbitrary value in n 0,1,2 and 3, corresponding amine cyclodextrin are followed successively by:Single-(6- amino -6- deoxidations)-β- Cyclodextrin, list-(6- ethylenediamine -6- deoxidations)Beta-cyclodextrin, list-(6- diethylenetriamine -6- deoxidations)Beta-cyclodextrin and single- (6- triethylene tetramine -6- deoxidations)Beta-cyclodextrin.
2. the inclusion compound of quinindium and amine cyclodextrin according to claim 1, it is characterised in that:Using solvent include method or Prepared by ultrasonic method, the molar ratio of wherein quinindium and amine cyclodextrin is 1:2~1:10.
3. the inclusion compound of quinindium and amine cyclodextrin according to claim 2, it is characterised in that:Using solvent inclusion method Preparation process is as follows:Quinindium is added in into the aqueous solution dissolved with amine cyclodextrin while stirring at 25 ~ 50 DEG C, continues to be protected from light After stirring 36 ~ 72 h, insoluble matter is filtered off, evaporated under reduced pressure solvent is up to quinindium and the inclusion compound of amine cyclodextrin.
4. the inclusion compound of quinindium and amine cyclodextrin according to claim 2, it is characterised in that:Using ultrasonic method Preparation process is as follows:Quinindium is added in amine cyclodextrin aqueous solution at 25 ~ 50 DEG C into sonic oscillation, then proceedes to keep away After 1 ~ 10 h of light ultrasound, insoluble matter is filtered off, evaporated under reduced pressure solvent is up to quinindium and the inclusion compound of amine cyclodextrin.
CN201810000390.0A 2018-01-02 2018-01-02 A kind of inclusion compound of quinindium and amine cyclodextrin Pending CN108239185A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810000390.0A CN108239185A (en) 2018-01-02 2018-01-02 A kind of inclusion compound of quinindium and amine cyclodextrin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810000390.0A CN108239185A (en) 2018-01-02 2018-01-02 A kind of inclusion compound of quinindium and amine cyclodextrin

Publications (1)

Publication Number Publication Date
CN108239185A true CN108239185A (en) 2018-07-03

Family

ID=62698448

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810000390.0A Pending CN108239185A (en) 2018-01-02 2018-01-02 A kind of inclusion compound of quinindium and amine cyclodextrin

Country Status (1)

Country Link
CN (1) CN108239185A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109134709A (en) * 2018-07-19 2019-01-04 昆明理工大学 The bonded object and its preparation method and application of the bonded open loop Cucurbituril of amido modification cyclodextrin
CN109180840A (en) * 2018-09-18 2019-01-11 昆明理工大学 A kind of acid-sensitive type ring dextrin and preparation method thereof
CN114105778A (en) * 2021-12-21 2022-03-01 重庆三峡学院 Preparation method of pentaerythrityl tetradiamine
CN114569742A (en) * 2022-05-09 2022-06-03 北京剂泰医药科技有限公司 Composition and preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104606681A (en) * 2009-05-13 2015-05-13 锡德克斯药物公司 Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
CN104826123A (en) * 2015-04-10 2015-08-12 昆明理工大学 Clathrate compound of oleanolic acid and amine cyclodextrin
CN104826124A (en) * 2015-04-10 2015-08-12 昆明理工大学 Chrysin and amine cyclodextrin clathrate
CN106038488A (en) * 2016-07-19 2016-10-26 重庆医科大学 Oil-in-water nano-emulsion capable of obviously improving bioavailability of insoluble medicament and preparation method for oil-in-water nano-emulsion

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104606681A (en) * 2009-05-13 2015-05-13 锡德克斯药物公司 Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
CN104826123A (en) * 2015-04-10 2015-08-12 昆明理工大学 Clathrate compound of oleanolic acid and amine cyclodextrin
CN104826124A (en) * 2015-04-10 2015-08-12 昆明理工大学 Chrysin and amine cyclodextrin clathrate
CN106038488A (en) * 2016-07-19 2016-10-26 重庆医科大学 Oil-in-water nano-emulsion capable of obviously improving bioavailability of insoluble medicament and preparation method for oil-in-water nano-emulsion

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
I.EL-GIBALY等: ""Quinidine-cyclodextrins inclusion complexes"", 《BULLETIN OF PHARMACEUTICAL SCIENCES》 *
国家食品药品监督管理局执业药师资格认证中心: "《药学专业知识(二)》", 30 April 2007, 中国中医药出版社 *
陈素文等: "《实用药物体液浓度测定》", 31 October 1994, 中国医药科技出版社 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109134709A (en) * 2018-07-19 2019-01-04 昆明理工大学 The bonded object and its preparation method and application of the bonded open loop Cucurbituril of amido modification cyclodextrin
CN109134709B (en) * 2018-07-19 2020-08-25 昆明理工大学 Amino modified cyclodextrin bonded ring-opening cucurbituril bonding compound and preparation method and application thereof
CN109180840A (en) * 2018-09-18 2019-01-11 昆明理工大学 A kind of acid-sensitive type ring dextrin and preparation method thereof
CN114105778A (en) * 2021-12-21 2022-03-01 重庆三峡学院 Preparation method of pentaerythrityl tetradiamine
CN114569742A (en) * 2022-05-09 2022-06-03 北京剂泰医药科技有限公司 Composition and preparation method and application thereof

Similar Documents

Publication Publication Date Title
CN108239185A (en) A kind of inclusion compound of quinindium and amine cyclodextrin
DE69130165T2 (en) CYCLODEXTRIN DERIVATIVES WITH INCREASED WATER-SOLUBILITY AND THEIR USE
CA1234106A (en) COMPOUNDS HAVING ANTIINFLAMMATORY ACTIVITY, OBTAINED BY COMPLEXATION WITH .beta.-CYCLODEXTRIN, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US8278437B2 (en) Hydroxypropyl-sulfobutyl-beta-cyclodextrin, the preparation method, the analytical method, and the pharmacutical application thereof
HU176215B (en) Process for preparing a cyclodextrin-indomethacin inclusion complex with a ratio of at about 2:1
CN109908116A (en) A kind of inclusion compound and preparation method thereof of cannabidiol and open loop Cucurbituril
CN100374468C (en) Synthetic process for water soluble sulfoalkyl ether-beta-cyclic dextrine
CN102716491B (en) Clathrate compound of artemisinin series and alkaline cyclodextrin and method for preparing same
AU675146B2 (en) New nimesulide salt cyclodextrin inclusion complexes
WO2015042759A1 (en) Carboxymethyl-hydroxypropyl-β-cyclodextrin and preparation method thereof
CN109867733A (en) The cyclodextrine derivatives and preparation method thereof of a kind of ferulic acid modification
WO1994028031A9 (en) New nimesulide salt cyclodextrin inclusion complexes
EP0422497B1 (en) Inclusion complexes with silybinin, their preparation and pharmaceutical compositions containing them
US20220008382A1 (en) Alcohol antidote
CN102898433B (en) Tetrandrine gallate and drug composition, preparation method and applications thereof
CN103462975A (en) Inclusion compound of mangiferin and alkaline cyclodextrin
CN104826124A (en) Chrysin and amine cyclodextrin clathrate
CN102861342B (en) Scutellarin prodrug using cyclodextrin as carrier and preparation method for scutellarin prodrug
EP1272531B8 (en) Crystalline mixtures of partial methyl ethers of beta-cyclodextrin and related compounds
CN108137714A (en) Novel methylated cyclodextrin and its production method
CN104826123B (en) A kind of inclusion compound of oleanolic acid and amine cyclodextrin
CN101264086A (en) Medicinal composition containing cefixime cyclodextrin inclusion compound and preparation thereof
Sun et al. Evaluation on the inclusion behavior of β-cyclodextrins with lycorine and its hydrochloride
CN102671213A (en) Scutellarin prodrug and preparation method thereof
CN110170058B (en) Abiraterone clathrate compound and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180703